Background: N-6 methylation (m6A) pushes forward an immense influence on the occurrence and development of lung adenocarcinoma (LUAD). However, the methylation on non-coding RNA in LUAD, especially long non-coding RNA (lncRNA), has not been received sufficient attention.
Methods: Spearman correlation analysis was used to screen lncRNA correlated with m6A regulators expression from the Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) repositories, respectively. Then, the least absolute shrinkage and selection operator (LASSO) was applied to build a risk signature consisting m6A-related lncRNA. Univariate and multivariate independent prognostic analysis were applied to evaluate the performance of signature in predicting patients' survival. Next, we applied Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG), and gene set enrichment analysis (GSEA) to conduct pathway enrichment analysis of 3344 different expression genes (DEGs). Finally, we set up a competing endogenous RNAs (ceRNA) network to this lncRNA.
Results: A total of 85 common lncRNAs were selected to acquire the components related to prognosis. The final risk signature established by LASSO regression contained 11 lncRNAs: ARHGEF26-AS1, COLCA1, CRNDE, DLGAP1-AS2, FENDRR, LINC00968, TMPO-AS1, TRG-AS1, MGC32805, RPARP-AS1, and TBX5-AS1. M6A-related lncRNA risk score could predict the prognostic of LUAD and was significantly associated with clinical pathological. And in the evaluation of lung adenocarcinoma tumor microenvironment (TME) by using ESTIMATE algorithm, we found a statistically significant correlation between risk score and stromal/immune cells.
Conclusion: M6A-related lncRNA was a potential prognostic and therapy target for lung adenocarcinoma.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8605119 | PMC |
| http://dx.doi.org/10.1002/jcla.23951 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A Case of Primary Lung Adenocarcinoma With Recurrent Brain Metastasis due to Transformation to Small Cell Carcinoma During Adjuvant Atezolizumab Therapy.
Thorac Cancer
December 2024
Department of Respiratory Medicine, Gunma University Graduate School of Medicine, Maebashi, Gunma, Japan.
Histologic transformation from non-small cell to small cell lung cancer (SCLC) is a resistance mechanism to immune checkpoint inhibitors. We report herein a case of lung adenocarcinoma who developed liver and brain metastases during adjuvant atezolizumab therapy. The patient underwent a craniotomy to resect a brain metastasis, which was pathologically diagnosed as SCLC.
View Article and Find Full Text PDFGenome-scale modeling identifies dynamic metabolic vulnerabilities during the epithelial to mesenchymal transition.
Commun Biol
December 2024
Department of Biomedical Engineering, University of Michigan, Ann Arbor, MI, USA.
Epithelial-to-mesenchymal transition (EMT) is a conserved cellular process critical for embryogenesis, wound healing, and cancer metastasis. During EMT, cells undergo large-scale metabolic reprogramming that supports multiple functional phenotypes including migration, invasion, survival, chemo-resistance and stemness. However, the extent of metabolic network rewiring during EMT is unclear.
View Article and Find Full Text PDFSquamous cell carcinoma predicts worse prognosis in stage IA (≤ 2 cm) non-small cell lung cancer patients following sublobectomy: a population-based study.
Sci Rep
December 2024
Department of Thoracic Surgery, the Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
Recent studies recommend sublobectomy as a surgical approach for non-small cell lung cancer (NSCLC) tumors that are 2 cm or smaller. However, it remains unclear whether NSCLC patients with squamous cell carcinoma (SCC) have comparable outcomes to those with adenocarcinoma (ADC) following sublobectomy. To that end, this study aims to compare the survival outcomes between SCC and ADC in patients with stage IA NSCLC (≤ 2 cm) who have undergone sublobectomy.
View Article and Find Full Text PDFTargeting mitochondrial RNAs enhances the efficacy of the DNA-demethylating agents.
Sci Rep
December 2024
Department of Chemical and Biomolecular Engineering, Korea Advanced Institute of Science and Technology (KAIST), Daejeon, 34141, Korea.
Hypomethylating agents (HMAs) such as azacytidine and decitabine are FDA-approved chemotherapy drugs for hematologic malignancy. By inhibiting DNA methyltransferases, HMAs reactivate tumor suppressor genes (TSGs) and endogenous double-stranded RNAs (dsRNAs) that limit tumor growth and trigger apoptosis via viral mimicry. Yet, HMAs show limited effects in many solid tumors despite the strong induction of TSGs and dsRNAs.
View Article and Find Full Text PDFMultimodal Deep Learning Fusing Clinical and Radiomics Scores for Prediction of Early-Stage Lung Adenocarcinoma Lymph Node Metastasis.
Acad Radiol
December 2024
School of Public Health, Jiangxi Medical College, Nanchang University, Nanchang 330006, China (C.X., L.D., W.C., M.H.); Jiangxi Provincial Key Laboratory of Disease Prevention and Public Health, Nanchang University, Nanchang 330006, China (C.X., L.D., W.C., M.H.). Electronic address:
Rationale And Objectives: To develop and validate a multimodal deep learning (DL) model based on computed tomography (CT) images and clinical knowledge to predict lymph node metastasis (LNM) in early lung adenocarcinoma.
Materials And Methods: A total of 724 pathologically confirmed early invasive lung adenocarcinoma patients were retrospectively included from two centers. Clinical and CT semantic features of the patients were collected, and 3D radiomics features were extracted from nonenhanced CT images.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!